Department of Radiation Oncology, University Hospital of Muenster, Muenster, Germany.
Department of Surgery, University Hospital of Muenster, Muenster, Germany.
Anticancer Res. 2020 Jun;40(6):3379-3386. doi: 10.21873/anticanres.14321.
BACKGROUND/AIM: Thyroid cancer (TC) is a relatively rare malignancy. The mainstay treatment is surgery followed by radioactive iodine (RAI) and medical systemic treatments. The role of external beam radiotherapy (EBRT) in TC is controversial regarding the survival benefits. The aim of this study was to analyse the effectiveness of EBRT for different forms of TC in different stages.
Between January 1990 and 2016, 75 patients underwent 255 radiotherapy (RT) courses at our Institution. Local control (LC) and progression-free survival (PFS) were analyzed.
The cohort consisted of 22 patients who received curative RT and 53 patients who received RT in a palliative setting. The estimated 5-year LC for the curative group was 92±8% and the palliative group 78±7%. The estimated 5-year PFS for the curative group was 27±9% and for palliative group 31±6%.
The addition of RT in TC seems to be safe and effective. Our analysis showed an excellent local control (median >15 years) regardless of the treatment setting.
背景/目的：甲状腺癌（TC）是一种相对罕见的恶性肿瘤。主要的治疗方法是手术，然后是放射性碘（RAI）和医学系统治疗。外照射放疗（EBRT）在 TC 中的作用在生存获益方面存在争议。本研究旨在分析 EBRT 在不同分期不同形式的 TC 中的有效性。
1990 年 1 月至 2016 年期间，75 名患者在我们机构接受了 255 次放疗（RT）治疗。分析局部控制（LC）和无进展生存期（PFS）。
该队列包括 22 名接受根治性 RT 的患者和 53 名接受姑息性 RT 的患者。根治性组的 5 年 LC 估计为 92±8%，姑息性组为 78±7%。根治性组的 5 年 PFS 估计为 27±9%，姑息性组为 31±6%。
在 TC 中添加 RT 似乎是安全有效的。我们的分析显示，无论治疗环境如何，局部控制都非常出色（中位数>15 年）。
